10-K: Puma Bio 2025: NERLYNX Sales Up, Alisertib Trials Advance Amid Legal Battles

Puma Biotechnology's 2025 Annual Report details increased NERLYNX product revenue, ongoing alisertib clinical trials, and significant legal challenges impacting international markets and patent validity.

Summary

• Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing innovative products for cancer care, primarily NERLYNX and the investigational drug alisertib.
• Total revenue for the year ended December 31, 2025, was $228.4 million, a slight decrease from $230.5 million in 2024.
• Product revenue, net, increased by $8.9 million to $204.1 million in 2025, driven by a 5.5% volume increase in NERLYNX bottles sold and a higher net selling price.
• Royalty revenue decreased by $11.0 million to $24.3 million in 2025, primarily due to reduced product sales by sub-licensees in international territories, particularly China.
• Net income for 2025 was $31.1 million, an increase from $30.3 million in 2024.
• Cash provided by operating activities was $41.8 million in 2025, up from $38.9 million in 2024.
• Research and development (R&D) expenses increased by $7.1 million to $62.1 million in 2025, mainly due to expanded alisertib development.
• Selling, general and administrative (SG&A) expenses decreased by $9.3 million to $70.8 million in 2025, primarily due to lower legal fees associated with the AstraZeneca litigation in the prior year.
• The company initiated the Phase II ALISCA-Lung1 trial for alisertib monotherapy in small cell lung cancer in February 2024 and the ALISCA-Breast1 Phase II trial in hormone receptor-positive, HER2-negative metastatic breast cancer in November 2024, with enrollment for the breast cancer trial completed in February 2026.
• In the AstraZeneca patent litigation, a jury awarded $107.5 million to Wyeth (Puma's licensor) for past infringement through December 31, 2023; however, the court later granted AstraZeneca's motion for judgment of invalidity on certain patent claims, a decision Wyeth is appealing.
• Multiple generic versions of NERLYNX have been approved in China (Acebright, Aosaikang, Convalife, Kelun), leading to ongoing patent infringement lawsuits and adverse rulings against Puma's patents in that region.
• The company recorded a partial release of $3.8 million of its valuation allowance related to deferred tax assets in 2025, driven by forecasted earnings in 2026.
• As of December 31, 2025, the company had an accumulated deficit of $1,283.8 million and outstanding indebtedness of $22.5 million under the Athyrium Notes, which mature on July 23, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with concerning developments. While US product revenue for NERLYNX increased and net income improved, the significant decline in international royalty revenue and adverse legal rulings regarding key patents, coupled with increasing generic competition in China and US healthcare reform pressures, present substantial headwinds for future growth and profitability. The ongoing development of alisertib is a positive, but its success is uncertain and costly.

Positives

• Product revenue, net, increased by $8.9 million to $204.1 million in 2025, driven by a 5.5% volume increase in NERLYNX bottles sold and a higher net selling price.
• Net income increased to $31.1 million in 2025 from $30.3 million in 2024, demonstrating continued profitability.
• Cash provided by operating activities increased to $41.8 million in 2025, indicating strong operational cash generation.
• Selling, general and administrative expenses decreased by $9.3 million in 2025, primarily due to lower legal fees.
• Enrollment for the ALISCA-Breast1 Phase II trial for alisertib in hormone receptor-positive, HER2-negative metastatic breast cancer was completed in February 2026, marking significant progress in pipeline development.
• Intracranial activity was observed for the combination of neratinib plus T-DM1 in TBCRC 022 cohorts, including in patients with prior T-DM1 exposure, suggesting a potential reversal of resistance to T-DM1.
• NERLYNX is included in the National Comprehensive Cancer Network (NCCN) Practice Guidelines for Breast Cancer (extended adjuvant HER2-positive, HR-positive, high risk of recurrence) and for Cervical Cancer (HER2-mutated recurrent/metastatic), indicating medical community recognition.
• A jury found in favor of Wyeth (Puma's licensor) in the AstraZeneca litigation, awarding $107.5 million for past infringement through December 31, 2023, although this was later challenged by a court ruling.
• A partial valuation allowance release of $3.8 million for deferred tax assets was recorded in 2025, driven by forecasted earnings in 2026, improving the net deferred tax asset position.

Negatives

• Total revenue decreased by $2.1 million in 2025 compared to 2024, primarily due to a significant drop in royalty revenue.
• Royalty revenue decreased by $11.0 million to $24.3 million in 2025, mainly due to decreased product sales by sub-licensees in China, indicating challenges in international markets.
• Research and development expenses increased by $7.1 million to $62.1 million in 2025, primarily due to expanded alisertib development, which will continue to be a significant cost.
• The court granted AstraZeneca's motion for judgment as a matter of law that the '314 and '162 patents are invalid, overturning a jury verdict that had awarded $107.5 million to Wyeth (Puma's licensor), creating uncertainty around intellectual property protection and potential future damages.
• Multiple generic versions of NERLYNX have been approved in China (Acebright, Aosaikang, Convalife, Kelun), and related patent infringement lawsuits have largely resulted in unfavorable outcomes for Puma, indicating increased competition and potential loss of market share in a key international territory.
• NERLYNX revenues are expected to be impacted by increased discounts (10% in initial coverage phase, 20% in catastrophic phase) under the Inflation Reduction Act's new discounting program, effective January 1, 2025.
• The One Big Beautiful Bill Act, enacted in July 2025, imposes significant reductions in Medicaid program funding, which could decrease enrollment and covered services, adversely affecting NERLYNX sales.
• Trump administration proposals (Globe and Guard regulations, December 2025) threaten to implement mandatory payment models with rebates based on 'most favored nation pricing,' potentially causing a drastic and negative shift in the U.S. pharmaceutical market.
• The company has an accumulated deficit of $1,283.8 million as of December 31, 2025, despite recent profitability.
• Diarrhea remains a frequently observed adverse event for neratinib-treated patients, with Grade 3 diarrhea incidence ranging from 13% to 33% in CONTROL trial cohorts, which could affect patient adherence and market acceptance.

Risks

• Inability to maintain profitability despite recent net income, with expectations of future operating losses due to ongoing development and commercialization costs.
• Dependence on NERLYNX as a single product for the vast majority of product revenue, making the company vulnerable to commercial fluctuations and market acceptance challenges.
• Inability to secure additional financing on favorable terms, or at all, which could force delays, limits, reductions, or termination of product development or commercialization efforts.
• Restrictions on business operations and financial flexibility imposed by the Note Purchase Agreement with Athyrium, including minimum revenue and cash balance covenants, with potential for default.
• The development of alisertib is expensive, lengthy, and unpredictable, with no assurance of successful development or regulatory approval.
• Interim, topline, and preliminary data from clinical trials may change as more patient data become available, potentially altering final conclusions.
• Undesirable side effects of NERLYNX, alisertib, or other drug candidates could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences post-marketing approval.
• Limited experience in marketing or distributing pharmaceutical products and risks associated with relying on a direct sales force in the United States.
• Dependence on a limited number of customers for a significant amount of total revenue (five customers comprised 27.3%, 17.0%, 16.4%, 13.1%, and 10.6% of product revenue in 2025).
• Reliance on international third-party sub-licensees for NERLYNX development and commercialization outside the United States, with risks of their failure to meet contractual or regulatory obligations.
• No experience in drug formulation or manufacturing, relying exclusively on third parties, which exposes the company to risks of supply disruption, quality issues, and regulatory non-compliance.
• Exposure to risks associated with public health emergencies or outbreaks of epidemics, pandemics, or contagious diseases.
• Significant reliance on information technology and vulnerability to failures, inadequacies, interruptions, or cybersecurity incidents.
• Dependence on in-licensed intellectual property (from Pfizer and Takeda), with risks of license termination if material breaches occur.
• Proprietary rights may not adequately protect intellectual property and potential products, and patents may be challenged, invalidated, or rendered unenforceable.
• Exposure to product liability claims and product recalls, which could result in substantial liabilities or limit commercialization.
• Potential for future strategic transactions (acquisitions, in-licensing) to increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities.
• The price of common stock could be subject to volatility related or unrelated to operations, including securities litigation risk.
• Issuance of stock to fund operations may dilute existing stockholders' equity interest.
• Incurrence of increased costs and demands upon management due to compliance with laws and regulations affecting public companies (e.g., Sarbanes-Oxley Act).
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate and timely financial statements.
• Lack of analyst coverage or adverse changes in recommendations could cause stock price and trading volume to decline.
• No cash dividends are foreseen in the foreseeable future, making capital appreciation the sole source of gain for investors.
• Ability to use net operating losses (NOLs) and research and development credit carryforwards to offset future taxable income may be subject to limitations under Sections 382 and 383 of the Internal Revenue Code.
• Health care reform measures (e.g., ACA, IRA, One Big Beautiful Bill Act, Trump administration proposals) may hinder or prevent product commercial success by reducing reimbursement or imposing price controls.
• Failure to comply with reporting and payment obligations under government pricing programs (Medicaid Drug Rebate Program, 340B program, VA FSS) could lead to penalties and sanctions.
• Subject to federal, state, and foreign healthcare fraud and abuse laws, false claims laws, and physician payment transparency laws, with potential for substantial penalties for non-compliance.
• Compliance with governmental regulation and other legal obligations related to privacy, data protection, and information security (e.g., GDPR, CCPA) could result in additional costs and liabilities.
• Intense competition in the cancer treatment market from major pharmaceutical, biotechnology, and specialty cancer companies, as well as academic institutions.
• Exposure to liability claims associated with the use of hazardous materials and chemicals in research and development activities.
• Loss of one or more key members of the management team could adversely affect the business.
• Inability to hire additional qualified personnel could harm business growth.
• Failure to successfully manage growth could strain management and administrative resources.
• Adverse effects from the current economic environment, including unemployment, inflation, and trade policies, could impact demand for products and financial stability of collaborators/customers.

Future Outlook

The company expects R&D expenses to increase in 2026 due to expanded alisertib development. It anticipates meeting with the FDA to explore a potential accelerated approval pathway for alisertib in small cell lung cancer. The company believes its existing cash, cash equivalents, marketable securities, and proceeds from product sales and sub-license payments are sufficient to satisfy operating cash and capital needs for at least one year after the filing date. Future profitability is uncertain beyond 2026 due to competitive pressures and the need for successful clinical development and approval of pipeline products.

Management Comments

• Our goal is to become a leading provider of advanced therapies for the treatment of various forms of cancer.
• An important near-term objective is to continue to execute our NERLYNX commercial plan by driving market penetration and duration of therapy consistent with the current NERLYNX label.
• We intend to pursue the development of alisertib in hormone receptor-positive breast cancer, as well as small cell lung cancer based on the prior clinical data that has been generated.
• We also plan to evaluate alisertib in biomarker focused populations where it has shown a higher degree of activity, such as patients with c-Myc amplification and RB1 loss/RB1 mutations, as we believe that this may provide a point of differentiation from the other drugs being developed in the treatment of these diseases.
• We believe this strategy minimizes our clinical development risk and allows us to accelerate the development and potential commercialization of current and future drug candidates.
• We believe that our existing cash and cash equivalents and marketable securities as of December 31, 2025, and proceeds that will become available to us through product sales and sub-license payments are sufficient to satisfy our operating cash and capital needs for at least one year after the filing of this Annual Report.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is highly competitive, with significant resources invested in cancer research and development. Puma Biotechnology faces intense competition from major pharmaceutical and biotechnology companies, as well as academic institutions, in the oncology space. The increasing focus on cost containment and pricing pressures from government and private payors, exacerbated by recent U.S. legislation like the Inflation Reduction Act and the One Big Beautiful Bill Act, poses significant challenges for drug commercialization and revenue generation across the industry. The ongoing legal challenges related to patent infringement and generic approvals in key international markets like China highlight the complex and litigious intellectual property landscape in oncology, which can significantly impact market exclusivity and revenue streams.

Comparison to Industry Standards

• NERLYNX competes with established HER2-blocking drugs such as trastuzumab, pertuzumab, lapatinib, T-DM1, famtrastuzumab deruxtecan, and tucatinib for HER2-positive breast cancer indications.
• Alisertib is being developed in a competitive landscape for small cell lung cancer, with other companies like Merck, AbbVie, Amgen, Daiichi Sankyo, and Jazz also developing drugs in this area.
• In hormone receptor-positive, HER2-negative metastatic breast cancer, the standard of care for first-line treatment involves Cyclin-dependent kinases (CDK) 4/6 inhibitors, against which alisertib combinations would compete.
• Recent clinical trial results from competitors, such as the DESTINY-Breast11 and DESTINY-Breast05 trials for trastuzumab deruxtecan and the CompassHER2 RD trial for tucatinib, indicate ongoing advancements and heightened competition in early stage HER2-positive breast cancer treatments.

Management Changes

Corporate Governance

Legal Proceedings

• **Legal Malpractice Suit**: The company re-filed a lawsuit in June 2023 against former attorneys for negligent handling of a prior case. The Superior Court dismissed the case in March 2024, but the North Carolina Court of Appeals reversed this dismissal on September 3, 2025, remanding the case for further proceedings. The defendants have petitioned the North Carolina Supreme Court for discretionary review.
• **AstraZeneca Litigation**: The company (and co-plaintiff Wyeth) sued AstraZeneca for patent infringement related to Tagrisso. A jury found in favor of Wyeth in May 2024, awarding $107.5 million for past infringement. However, the court later granted AstraZeneca's motion for judgment as a matter of law on August 14, 2024, finding the asserted patents invalid. Wyeth filed a notice of appeal on September 12, 2024, and briefing on the appeal is complete.
• **Acebright China Litigation**: Acebright received NMPA approval for a generic NERLYNX in China on September 12, 2023, following unfavorable CNIPA administrative decisions against Puma's patent claims. Puma's subsequent civil lawsuits against Acebright for infringement were withdrawn, and a first-instance court decision on September 28, 2025, found no infringement by Acebright.
• **Aosaikang China Litigation**: NMPA approved Aosaikang's ANDA for a generic NERLYNX in China on October 22, 2024, after CNIPA decisions largely went against Puma's patent claims.
• **Convalife China Litigation**: NMPA approved Convalife's ANDA for a generic NERLYNX in China on June 28, 2024, following CNIPA decisions largely unfavorable to Puma's patent claims.
• **Kelun China Litigation**: NMPA approved Kelun's ANDA for a generic NERLYNX in China on September 9, 2025, after Puma withdrew its administrative determination requests.
• **Demai Litigation**: The company filed a lawsuit against Demai in September/October 2024 for patent infringement related to a generic NERLYNX ANDA. Lawsuits were withdrawn in February 2025 to file an Article 76 petition with CNIPA, which was accepted on February 21, 2025. A nine-month stay on Demai's ANDA was requested on March 18, 2025.
• **Hexal European Patent Opposition (EP3000467)**: Oppositions were filed against European Patent No. EP3000467. Oral proceedings in April 2025 upheld the patent as amended, covering NERLYNX's EMA-approved indication. Hexal, Generics, and Wyeth filed appeals in June 2025, with Alfred E. Tiefenbacher withdrawing its appeal in December 2025. Wyeth responded to opponents' grounds of appeal in January 2026.
• **Hexal European Patent Opposition (EP3175853)**: An opposition was filed by Sandoz AG in July 2024 against European Patent No. EP3175853 (combination of neratinib and capecitabine). Oral proceedings are scheduled for April 16, 2026.

Stakeholder Impact

• **Shareholders**: Face potential for dilution from future equity raises, stock price volatility due to clinical trial results, regulatory decisions, and litigation outcomes. Their investment is impacted by the company's ability to maintain profitability and commercial success of NERLYNX and alisertib.
• **Patients**: Benefit from continued access to NERLYNX for HER2-positive breast cancer and the potential for new treatment options with alisertib development. They face the known risk of side effects, particularly diarrhea, associated with NERLYNX.
• **Employees**: The company maintains a workforce of 179 full-time employees as of December 31, 2025, with competitive compensation, benefits, and a flexible work environment. Management distraction due to ongoing litigation could indirectly impact employee focus and morale.
• **Customers (Specialty Pharmacies/Distributors)**: Continue to distribute NERLYNX, with their sales volumes and profitability influenced by market demand, pricing, and reimbursement changes.
• **Sub-licensees**: Responsible for international development and commercialization of NERLYNX. Their performance directly impacts Puma's royalty revenue, and challenges in these markets (e.g., generic competition in China) reduce the value derived from these partnerships.
• **Creditors (Athyrium)**: Hold secured promissory notes with an outstanding balance of $22.5 million, maturing in July 2026. Their investment is subject to the company's compliance with financial covenants, including minimum cash balances and product revenue targets.
• **Regulatory Bodies (FDA, EMA, NMPA)**: Continue to oversee drug approvals, post-marketing requirements, and compliance. Their decisions on new indications, labeling, and generic approvals directly impact the company's market access and commercial potential.

Next Steps

• Continue to execute the NERLYNX commercial plan by driving market penetration and duration of therapy in the United States.
• Pursue regulatory approval and commercialization of NERLYNX in additional countries worldwide through sub-license agreements.
• Advance the development of alisertib in hormone receptor-positive breast cancer and small cell lung cancer.
• Evaluate alisertib in biomarker-focused populations (c-Myc amplification and RB1 loss/mutations) to assess enhanced efficacy.
• Perform an initial interim analysis for biomarkers and efficacy in the ALISCA-Lung1 trial.
• Anticipate meeting with the FDA to explore the potential for an accelerated approval pathway for alisertib in small cell lung cancer.
• Focus future clinical development of alisertib in combination with endocrine therapy for HER2-negative, hormone receptor-positive breast cancer patients with potential biomarkers, pending ALISCA-Breast1 study outcome.
• Wyeth is appealing the District Court's judgment of patent invalidity in the AstraZeneca litigation.
• Oral proceedings are scheduled for April 16, 2026, for the opposition against European Patent No. EP3175853.
• The North Carolina Supreme Court has not yet decided whether to accept the legal malpractice case for review.
• Monitor the formal adoption and phased implementation of proposed revisions to EU pharmaceutical legislation, expected in early 2026 and entering application from 2028.
• Continue to evaluate the potential impact of the company's 'specified small manufacturer' status under the IRA on future revenues.
• Management will continue to evaluate the realizability of deferred tax assets on a quarterly basis.

Key Dates

Recommendation

The company shows some positive signs with increased US product revenue for NERLYNX and progress in alisertib clinical trials. However, significant headwinds exist, including declining international royalty revenue due to generic competition in China, adverse legal rulings on key patents (AstraZeneca litigation), and the potential negative impact of US healthcare reform on future revenues. The substantial accumulated deficit and ongoing need for financing, coupled with the inherent risks of single-product dependence and drug development, suggest a 'hold' recommendation. Investors should monitor the outcomes of ongoing litigation, the commercial performance of NERLYNX in the face of generic competition and policy changes, and the progress of alisertib's clinical development.

Keywords

Puma Biotechnology, NERLYNX, neratinib, alisertib, HER2-positive breast cancer, small cell lung cancer, biopharmaceutical, oncology, clinical trials, FDA approval, patent litigation, drug development, cancer treatment, pharmaceutical sales, biomarker, Aurora Kinase A inhibitor, tyrosine kinase inhibitor, SEC filing, 10-K, healthcare reform